Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
HERAN Partners is a Belgium-based venture capital investment fund founded in 2019. The firm focuses on creating significant impacts within the life sciences and healthcare sectors. Established by a group of entrepreneurs and investors with backgrounds in scientific and technological innovation, HERAN Partners aims to support ventures that improve and disrupt healthcare through innovation and technology.
As of 2026, HERAN Partners manages a total of €90 million across its funds, with a portfolio of 15 companies. The firm has made notable strides in the healthcare investment space, particularly in MedTech and digital health. Their headquarters is located in Antwerp, Belgium, and they have expanded their geographic focus to include the Netherlands, Spain, and the United Kingdom.
HERAN Partners has achieved a realization rate of approximately 27% from its first fund, with four successful exits to date, including icometrix, UgenTec, PharmaFluidics, and BlueBee. The firm is recognized for its commitment to enhancing patient care and improving drug development efficiency through innovative solutions.
HERAN Partners invests in companies that demonstrate feasibility for disruptive innovation in healthcare and life sciences. Their investment strategy encompasses seed, Series A, and Series B stages, focusing on solutions that address unmet market needs. They target investments in hardware, software, and services that enhance patient care and improve efficiency in drug development.
The firm seeks differentiated approaches built on solid intellectual property and know-how. They are particularly interested in ventures that leverage innovative technology to disrupt healthcare. Their investment thesis emphasizes supporting bold innovators who are addressing real-world clinical problems, particularly in the life sciences, MedTech, and digital health sectors.
HERAN Partners is open to a variety of investment structures and often leads or co-leads funding rounds. Their geographic focus includes Belgium, the Netherlands, Spain, and the UK, reflecting a commitment to the European healthcare market.
HERAN Partners has a diverse portfolio of 15 companies, focusing on innovative solutions in healthcare and life sciences. Notable portfolio companies include:
Katleen Vandersmissen - Managing Partner: Katleen has extensive experience in venture capital and healthcare investments, focusing on supporting innovative startups in the life sciences sector.
Herman Verrelst - Founding Partner & Senior Advisor: Herman has a strong background in scientific innovation and has been instrumental in establishing HERAN Partners.
Mercedes Tuin - Partner: Mercedes joined HERAN Partners in late 2025, bringing experience from her previous role at a Dutch development investor, focusing on the Netherlands pipeline.
Raf Roelands - Partner: Raf has been with HERAN Partners since its inception and has played a key role in managing investments and supporting portfolio companies.
Wim Van Looveren - Finance Director: Wim oversees the financial operations of HERAN Partners, ensuring sound financial management and reporting.
Emke Goijens - Operations & Communications: Emke manages the operational aspects and communications strategy of the firm.
Geoffrey D'hondt - Investment Director: Geoffrey leads investment efforts, focusing on sourcing and evaluating potential portfolio companies.
Margot Huysmans - Analyst: Margot supports the investment team with research and analysis of market trends and potential investments.
Joris Mortelmans - Partner & Senior Advisor: Joris brings a wealth of experience in healthcare investments and strategic guidance to portfolio companies.
Annie Vereecken - Founding Partner & Senior Advisor: Annie is a serial medtech and biotech investor, known for her successful exits and deep industry knowledge.
To pitch HERAN Partners, founders should use the contact form available at heranpartners.com/contact. It is advisable to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. HERAN Partners values clear communication and expects a well-structured presentation.
Response times may vary, but founders can generally expect to hear back within a few weeks. Warm introductions are preferred, especially from mutual connections within the healthcare or investment sectors.
In 2023, HERAN Partners made significant investments in the healthcare sector, including a €6 million growth round in Pharmacelera, a company specializing in AI-driven drug discovery technologies. They also co-led a €6.5 million round in Hypervision Surgical, which focuses on AI-enhanced surgical outcomes.
Additionally, HERAN Partners co-led a €5 million seed investment in Nuclivision, a company developing software solutions for nuclear imaging. These investments reflect HERAN's commitment to supporting innovative healthcare solutions that address real-world clinical problems.
What stages does HERAN Partners invest in?
HERAN Partners invests in seed, Series A, and Series B stages, focusing on companies that demonstrate potential for disruptive innovation in healthcare and life sciences.
What sectors does HERAN Partners focus on?
The firm primarily targets investments in healthcare, biotech, digital health, and MedTech sectors, seeking solutions that address unmet market needs.
How can I pitch to HERAN Partners?
Founders can submit their pitch through the contact form available on the HERAN Partners website at heranpartners.com/contact. It is recommended to include a detailed overview of the business model, market opportunity, and team background.
What makes HERAN Partners different from other investors?
HERAN Partners emphasizes mentorship and access to a robust network of industry experts, focusing on supporting bold innovators with differentiated approaches built on solid intellectual property.
What is the typical check size for investments?
While specific check sizes are not disclosed, HERAN Partners typically invests in early-stage rounds, which may range from several hundred thousand to a few million euros, depending on the stage and company.
What is the geographic focus of HERAN Partners?
HERAN Partners primarily invests in companies based in Belgium, the Netherlands, Spain, and the United Kingdom, reflecting a strong commitment to the European healthcare market.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.